Table of Content

Executive Summary



Chapter 1 – Introduction



Chapter 2 – Trends in infectious diseases dealmaking



2.1. Introduction

2.2. Infectious diseases partnering over the years

2.3. Infectious diseases partnering by deal type

2.4. Infectious diseases partnering by industry sector

2.5. Infectious diseases partnering by stage of development

2.6. Infectious diseases partnering by technology type

2.7. Infectious diseases partnering by therapeutic indication



Chapter 3 – Financial deal terms for infectious diseases partnering



3.1. Introduction

3.2. Disclosed financials terms for infectious diseases partnering

3.3. Infectious diseases partnering headline values

3.4. Infectious diseases deal upfront payments

3.5. Infectious diseases deal milestone payments

3.6. Infectious diseases royalty rates



Chapter 4 – Leading infectious diseases deals and dealmakers



4.1. Introduction

4.2. Most active in infectious diseases partnering

4.3. List of most active dealmakers in infectious diseases

4.4. Top infectious diseases deals by value



Chapter 5 – Infectious diseases contract document directory



5.1. Introduction

5.2. Infectious diseases partnering deals where contract document available



Chapter 6 – Infectious diseases dealmaking by therapeutic target



6.1. Introduction

6.2. Deals by infectious diseases therapeutic target



Deal directory



Deal directory – Infectious diseases deals by company A-Z 2016 to 2023

Deal directory – Infectious diseases deals by technology type 2016 to 2023



Deal type definitions



About Wildwood Ventures



Current Partnering

Current Agreements

Recent report titles from CurrentPartnering



Table of figures



Figure 1: Infectious diseases partnering since 2016

Figure 2: Infectious diseases partnering by deal type since 2016

Figure 3: Infectious diseases partnering by industry sector since 2016

Figure 4: Infectious diseases partnering by stage of development since 2016

Figure 5: Infectious diseases partnering by technology type since 2016

Figure 6: Infectious diseases partnering by indication since 2016

Figure 7: Infectious diseases deals with a headline value

Figure 8: Infectious diseases deals with upfront payment values

Figure 9: Infectious diseases deals with milestone payment

Figure 10: Infectious diseases deals with royalty rates

Figure 11: Active infectious diseases dealmaking activity since 2016

Figure 12: Top infectious diseases deals by value since 2016